---
title: "Drug Eruptions"
order: 5
category: "Dermatology"
---

# Drug Eruptions

## Overview

Drug eruptions, also known as cutaneous adverse drug reactions, are unwanted skin manifestations caused by medications. They represent one of the most common adverse effects of pharmaceutical agents, accounting for 2-3% of all hospital admissions and occurring in 1-3% of hospitalized patients. Drug eruptions range from mild, self-limited rashes to severe, life-threatening conditions. Prompt recognition and management are essential to prevent serious complications and guide future drug use.

### Classification
- **Type I (IgE-mediated)**: Urticaria, angioedema, anaphylaxis
- **Type II (Cytotoxic)**: Drug-induced pemphigus, hemolytic anemia
- **Type III (Immune complex)**: Serum sickness, vasculitis
- **Type IV (T-cell mediated)**: Exanthematous drug eruption, SJS/TEN, DRESS
- **Pseudoallergic**: Direct mast cell activation (not immune-mediated)
- **Non-immune**: Phototoxicity, pigmentation changes

### Epidemiology
- **Incidence**: 2-3% of outpatients, 10-20% of hospitalized patients
- **Age**: More common in elderly due to polypharmacy
- **Gender**: Women more commonly affected (2:1)
- **Most common type**: Exanthematous (morbilliform) eruption (90%)
- **Severe reactions**: Rare (<1% of drug eruptions)

### Risk Factors
- **Polypharmacy**: Multiple medications increase risk
- **Age**: Elderly and children at higher risk
- **Gender**: Women more susceptible
- **HIV infection**: Higher incidence and severity (especially with sulfonamides)
- **Genetics**: HLA associations with certain reactions
- **Renal/hepatic impairment**: Altered drug metabolism
- **Previous drug reactions**: History increases risk of future reactions

### Temporal Patterns
- **Acute**: Within hours to days (urticaria, anaphylaxis)
- **Subacute**: 1-2 weeks (most common for exanthematous)
- **Delayed**: Weeks to months (lichenoid reactions, lupus-like syndrome)
- **Withdrawal**: After discontinuation (corticosteroids)

## Approach to Drug Eruptions

### Clinical Evaluation

#### History
- **Medication review**: All medications including OTC, herbals, supplements
- **Timing**: Onset of rash relative to drug initiation
- **New medications**: Within past 2-4 weeks
- **Previous exposures**: Prior use of same medication
- **Symptoms**: Fever, pruritus, mucosal involvement, systemic symptoms
- **Previous drug reactions**: History and details

#### Physical Examination
- **Morphology**: Type of lesions (macules, papules, vesicles, pustules, purpura)
- **Distribution**: Localized vs generalized, symmetric vs asymmetric
- **Configuration**: Pattern of lesions
- **Mucous membranes**: Oral, genital, conjunctival involvement
- **Systemic signs**: Fever, lymphadenopathy, hepatosplenomegaly

#### Laboratory Evaluation (for Severe Reactions)
- **Complete blood count**: Eosinophilia, atypical lymphocytes
- **Liver function tests**: Hepatitis in DRESS, SJS/TEN
- **Renal function**: Nephritis possible
- **Inflammatory markers**: ESR, CRP
- **Skin biopsy**: If diagnosis uncertain or severe reaction

### Diagnostic Approach

#### Causality Assessment
- **Naranjo scale**: Probability of drug causation
- **Timing**: Compatible with known latency period
- **Exclusion**: Other causes ruled out
- **Dechallenge**: Improvement after drug discontinuation
- **Rechallenge**: Not recommended for severe reactions

#### Identifying Culprit Drug
- **Most recent additions**: Focus on drugs started in past 2-4 weeks
- **Known offenders**: Antibiotics, anticonvulsants, NSAIDs
- **Half-life**: Drugs with longer half-lives may have delayed onset
- **Multiple drugs**: May need to discontinue all non-essential medications

## Common Drug Eruption Patterns

### Exanthematous (Morbilliform) Drug Eruption

#### Overview
- **Most common**: 90% of all drug eruptions
- **Mechanism**: Type IV delayed hypersensitivity (T-cell mediated)
- **Latency**: 7-14 days after drug initiation (may be 2-3 days if re-exposure)
- **Prognosis**: Self-limited, benign

#### Clinical Presentation
- **Morphology**: Symmetric, erythematous macules and papules
- **Pattern**: Morbilliform ("measles-like"), may become confluent
- **Distribution**: Trunk and extremities, spares face initially
- **Progression**: Spreads centrally to peripherally
- **Pruritus**: Usually present, mild to moderate
- **Mucous membranes**: Typically spared
- **Systemic symptoms**: Absent or low-grade fever

#### Common Causative Drugs
- **Antibiotics**: Penicillins, cephalosporins, sulfonamides
- **Anticonvulsants**: Phenytoin, carbamazepine, phenobarbital
- **Allopurinol**
- **NSAIDs**
- **Antiretrovirals**: Especially nevirapine

#### Diagnosis
- **Clinical**: Characteristic appearance and timing
- **Biopsy**: Usually not needed; shows interface dermatitis if performed
- **Differentiation**: From viral exanthem (history, exposure)

#### Management
- **Mild cases**: May continue drug if essential and reaction mild
- **Moderate to severe**: Discontinue drug
- **Symptomatic treatment**:
  - Topical corticosteroids: Mid-potency for body
  - Oral antihistamines: Sedating at bedtime (hydroxyzine, diphenhydramine)
  - Emollients: Frequent application
  - Cool compresses: For comfort
- **Resolution**: 1-2 weeks after drug discontinuation
- **Desquamation**: May occur during resolution

#### Special Consideration: Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Evolution
- **Monitor**: For fever, facial edema, lymphadenopathy
- **Laboratory**: If symptoms develop (CBC with differential, LFTs)
- **DRESS risk**: Anticonvulsants, allopurinol, sulfonamides

### Urticaria and Angioedema

#### Overview
- **Prevalence**: Second most common drug eruption
- **Mechanism**: Type I (IgE-mediated) or direct mast cell activation (pseudoallergic)
- **Onset**: Minutes to hours (IgE-mediated), can be delayed (pseudoallergic)

#### Clinical Presentation
- **Urticaria (Hives)**:
  - Erythematous, edematous wheals
  - Pruritic
  - Individual lesions resolve <24 hours
  - New lesions continue to appear
  - Size and shape vary
- **Angioedema**:
  - Deeper dermal and subcutaneous edema
  - Face, lips, tongue, hands, feet, genitals
  - Non-pitting, skin-colored to erythematous
  - May affect airway (medical emergency)

#### Common Causative Drugs
**IgE-mediated:**
- **Antibiotics**: Penicillins, cephalosporins
- **Muscle relaxants**: Used in anesthesia
- **Biological agents**: Monoclonal antibodies
- **Latex**: In medical settings

**Pseudoallergic (direct mast cell activation):**
- **NSAIDs**: Aspirin, ibuprofen
- **Opioids**: Morphine, codeine
- **Vancomycin**: "Red man syndrome"
- **Radiocontrast media**
- **ACE inhibitors**: Angioedema without urticaria

#### Diagnosis
- **Clinical**: Characteristic transient wheals
- **Timing**: Immediate (minutes) suggests IgE-mediated
- **Skin testing**: May be done for IgE-mediated (e.g., penicillin)
- **Tryptase**: Elevated if measured during reaction (anaphylaxis)

#### Management
**Acute Treatment:**
- **Discontinue drug**: Immediately
- **Antihistamines**:
  - H1 blockers: Cetirizine 10 mg, fexofenadine 180 mg, loratadine 10 mg (may double or triple dose)
  - H2 blockers: Add famotidine or ranitidine for refractory cases
- **Corticosteroids**: Prednisone 40-60 mg daily for 3-7 days if severe
- **Epinephrine**: 0.3-0.5 mg IM if signs of anaphylaxis (hypotension, wheezing, airway compromise)

**Airway Management (Angioedema):**
- **Monitor closely**: Risk of airway obstruction
- **Epinephrine**: Early use if tongue or airway swelling
- **Intubation**: May be necessary for severe cases
- **ACE inhibitor angioedema**: May be bradykinin-mediated, not responsive to antihistamines
  - Fresh frozen plasma, ecallantide, or icatibant for refractory cases

**Prevention:**
- **Avoid culprit drug**: Document allergy
- **NSAIDs**: If pseudoallergic, avoid all NSAIDs (cross-reactivity)
- **Aspirin desensitization**: If aspirin needed for cardiac indication
- **Premedication**: For radiocontrast (corticosteroids, antihistamines)

### Fixed Drug Eruption (FDE)

#### Overview
- **Unique feature**: Recurs at same anatomic site(s) with re-exposure
- **Mechanism**: Type IV delayed hypersensitivity
- **Latency**: 30 minutes to 8 hours after re-exposure (first exposure 1-2 weeks)
- **Residual pigmentation**: Hallmark feature

#### Clinical Presentation
- **Morphology**: Solitary or few round, erythematous to violaceous patches or plaques
- **Size**: 2-10 cm typically
- **Center**: May blister or erode
- **Distribution**: Can occur anywhere, common sites:
  - Genitals (most common): Penis, vulva
  - Lips, oral mucosa
  - Hands, feet
  - Trunk
- **Symptoms**: Burning or pruritus
- **Resolution**: Leaves hyperpigmentation (key diagnostic feature)
- **Recurrence**: Same site(s) with drug re-exposure, may develop new sites

**Generalized Bullous FDE:**
- Severe variant with widespread bullous lesions
- Mimics SJS/TEN but has recurrent history and residual pigmentation
- Systemic symptoms less severe than SJS/TEN

#### Common Causative Drugs
- **Antibiotics**: Sulfonamides, tetracyclines, metronidazole
- **NSAIDs**: Naproxen, ibuprofen, piroxicam
- **Acetaminophen**
- **Barbiturates**
- **Antihistamines**: Pseudoephedrine
- **Antifungals**: Fluconazole, terbinafine

#### Diagnosis
- **Clinical**: Recurrence at same site, residual pigmentation
- **History**: Previous episodes with drug re-exposure
- **Biopsy**: Interface dermatitis, pigment incontinence
- **Oral provocation**: Can confirm but not routinely done (risk of recurrence)
- **Patch testing**: Low sensitivity

#### Management
- **Discontinue drug**: Immediately
- **Symptomatic**:
  - Topical corticosteroids: High-potency for lesions
  - Oral antihistamines: For pruritus
  - Cool compresses
- **Resolution**: Days to weeks, pigmentation persists months to years
- **Avoidance**: Culprit drug and structurally similar drugs
- **Documentation**: Alert bracelet if severe

### Photosensitivity Reactions

#### Overview
- **Mechanism**: Drug + UV radiation → skin damage
- **Types**: Phototoxic (more common) vs photoallergic

#### Phototoxic Reactions
**Mechanism:**
- Non-immunologic
- Drug absorbs UV → generates reactive oxygen species → direct cell damage
- Dose-dependent
- Can occur on first exposure

**Clinical Features:**
- **Resembles exaggerated sunburn**: Erythema, edema, pain
- **Distribution**: Only sun-exposed areas, sharp cutoff at clothing lines
- **Onset**: Minutes to hours after sun exposure
- **Severity**: Correlates with drug and UV dose
- **No recurrence**: If drug avoided
- **May develop**: Hyperpigmentation, especially with certain drugs

**Common Causative Drugs:**
- **Antibiotics**: Tetracyclines (especially doxycycline), fluoroquinolones
- **Diuretics**: Furosemide, thiazides
- **NSAIDs**: Ketoprofen, piroxicam, naproxen
- **Antifungals**: Voriconazole (severe, with pseudoporphyria)
- **Chemotherapy**: 5-fluorouracil, dacarbazine
- **Amiodarone**: Blue-gray pigmentation
- **Retinoids**: Isotretinoin, acitretin

**Management:**
- Stop drug if possible
- Sun protection: Avoid sun, broad-spectrum sunscreen, protective clothing
- Cool compresses, emollients
- Topical corticosteroids: For inflammation
- NSAIDs: For pain
- Resolution: Days to weeks

#### Photoallergic Reactions
**Mechanism:**
- Immune-mediated (Type IV)
- Drug + UV → hapten → T-cell response
- Not dose-dependent
- Requires sensitization (prior exposure)

**Clinical Features:**
- **Resembles eczema**: Erythema, papules, vesicles, pruritus
- **Distribution**: Sun-exposed areas, may spread beyond
- **Onset**: 24-48 hours after sun exposure
- **Persistence**: May persist despite drug discontinuation
- **Cross-reactivity**: Possible with structurally similar compounds

**Common Causative Drugs:**
- **NSAIDs**: Ketoprofen (most common photoallergen)
- **Antimicrobials**: Sulfonamides, quinolones
- **Sunscreens**: Oxybenzone, octocrylene
- **Fragrances**: Musk ambrette

**Management:**
- Discontinue drug
- Topical corticosteroids: Mid- to high-potency
- Oral corticosteroids: If severe
- Antihistamines: For pruritus
- Sun protection
- May take weeks to resolve

**Photodistributed Drug Eruption:**
- Drug eruption that preferentially involves sun-exposed areas
- Not true photosensitivity (doesn't require UV + drug interaction)
- Examples: Hydrochlorothiazide, calcium channel blockers, certain antimalarials

### Drug-Induced Hyperpigmentation

#### Overview
- **Common**: Many drugs can cause pigmentation changes
- **Mechanisms**: Melanin stimulation, drug/metabolite deposition, post-inflammatory
- **Distribution**: May be localized or generalized

#### Clinical Patterns and Drugs

**Diffuse Hyperpigmentation:**
- **Antimalarials**: Chloroquine, hydroxychloroquine (blue-gray, shins, face)
- **Chemotherapy**: Bleomycin (flagellate hyperpigmentation), busulfan (diffuse brown)
- **Clofazimine**: Red-brown to nearly black

**Localized/Patterned:**
- **Minocycline**: Blue-gray (types I, II, III)
  - Type I: Blue-black in scars, areas of inflammation
  - Type II: Blue-gray on shins
  - Type III: Diffuse muddy brown
- **Amiodarone**: Blue-gray on sun-exposed areas
- **Zidovudine**: Nail pigmentation, brown longitudinal bands

**Mucosal:**
- **Antimalarials**: Oral mucosa, palate
- **Minocycline**: Teeth (if used in childhood), oral mucosa
- **Chemotherapy**: Nails, oral mucosa

**Fixed drug-induced pigmentation:**
- Residual pigmentation from fixed drug eruption

#### Management
- **Discontinue drug if possible**
- **Sun protection**: Prevent darkening
- **Slow fading**: May take months to years
- **Laser therapy**: Q-switched lasers for some types
- **Persistence**: Some pigmentation may be permanent

## Severe Cutaneous Adverse Reactions (SCARs)

### Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)

#### Overview
- **Spectrum of severity**: SJS and TEN are on spectrum based on extent of involvement
- **SJS**: <10% body surface area (BSA) involvement
- **SJS-TEN overlap**: 10-30% BSA
- **TEN**: >30% BSA
- **Mechanism**: Type IV delayed hypersensitivity, cytotoxic T-cells and NK cells
- **Mortality**: SJS 1-5%, TEN 25-35%

#### Pathophysiology
- **Keratinocyte apoptosis**: Fas-FasL, granulysin, perforin/granzyme pathways
- **Genetic factors**: HLA associations with specific drugs:
  - HLA-B*15:02: Carbamazepine-induced SJS/TEN (Han Chinese, Southeast Asians)
  - HLA-B*58:01: Allopurinol-induced SJS/TEN (Han Chinese, Koreans, Thais)
  - HLA-B*57:01: Abacavir hypersensitivity

#### Clinical Presentation

**Prodrome (1-3 days before rash):**
- Fever (>38.5°C)
- Malaise, fatigue
- Arthralgia, myalgia
- Upper respiratory symptoms: Cough, sore throat
- Ocular symptoms: Burning, conjunctivitis

**Cutaneous Manifestations:**
- **Early**: Ill-defined erythematous macules with dusky centers
- **Target lesions**: Atypical targets (two zones, dusky center), unlike EM
- **Distribution**: Face, trunk → extremities
- **Progression**: Macules coalesce, develop flaccid bullae
- **Nikolsky sign**: Positive (lateral pressure causes epidermis to separate)
- **Denuded areas**: Skin sloughs, resembles scalded appearance
- **Pain**: Severe, skin feels burned

**Mucosal Involvement (90-95%):**
- **Oral**: Hemorrhagic erosions, crusting of lips
- **Ocular**: Conjunctivitis, photophobia, erosions
- **Genital**: Erosions, painful
- **Respiratory**: Tracheobronchial involvement (dyspnea, hypoxia)
- **Gastrointestinal**: Esophageal, gastric erosions

#### Common Causative Drugs
- **Antibiotics**: Sulfonamides (most common), beta-lactams, fluoroquinolones
- **Anticonvulsants**: Aromatic anticonvulsants (phenytoin, carbamazepine, phenobarbital, lamotrigine)
- **Allopurinol**: Especially at higher doses, renal impairment
- **NSAIDs**: Oxicam class (piroxicam, meloxicam)
- **Antiretrovirals**: Nevirapine
- **Mycoplasma pneumoniae**: Can cause SJS (especially in children)

#### Diagnosis
- **Clinical**: Characteristic features, mucosal involvement, Nikolsky sign
- **Skin biopsy**: Full-thickness epidermal necrosis, minimal inflammation
- **Exclusion**: Staphylococcal scalded skin syndrome (SSSS - affects neonates/children, no mucosal involvement, intraepidermal split)

#### Severity Assessment
- **SCORTEN**: Severity-of-illness score for TEN (predicts mortality)
  - Age >40 years
  - Malignancy
  - Heart rate >120
  - Initial BSA involved >10%
  - Serum BUN >28 mg/dL (10 mmol/L)
  - Serum glucose >252 mg/dL (14 mmol/L)
  - Serum bicarbonate <20 mEq/L
  - **Score 0-1**: <5% mortality
  - **Score ≥5**: >90% mortality

#### Complications
- **Acute**:
  - Sepsis (most common cause of death)
  - Fluid/electrolyte imbalance
  - Respiratory failure
  - GI bleeding
  - Renal failure
- **Ocular** (most common long-term):
  - Synechiae, scarring
  - Dry eyes, corneal damage
  - Vision loss
- **Cutaneous**: Scarring, pigmentary changes
- **Other**: Vaginal stenosis, esophageal strictures, bronchiolitis obliterans

#### Management

**Immediate Actions:**
- **Stop all possible causative drugs**: Immediately
- **Hospitalization**: ICU or burn unit for TEN, severe SJS
- **Supportive care**: Cornerstone of management

**Supportive Care:**
- **Wound care**:
  - Gentle handling, minimize trauma
  - Non-adherent dressings
  - Petroleum-based or antimicrobial ointments
  - Debride only loose tissue
- **Fluid/electrolyte replacement**: Burn formula initially, adjust based on losses
- **Nutrition**: High-protein, high-calorie (enteral preferred)
- **Temperature regulation**: Warming blankets (increased insensible losses)
- **Pain control**: IV opioids typically required
- **Infection surveillance**: Daily cultures if fever/deterioration, antibiotics only if documented infection
- **Ophthalmology**: Daily evaluation, topical lubrication, lysis of synechiae
- **Pulmonary**: Bronchoscopy and pulmonary toilet if respiratory involvement
- **Foley catheter**: If genital involvement, prevent vaginal synechiae (mold in females)

**Specific Therapies (Controversial):**
- **Corticosteroids**:
  - High-dose IV methylprednisolone: Used by some centers
  - Controversial: May increase infection risk, conflicting data on benefit
  - If used: Early in course, short duration
- **IVIG (Intravenous Immunoglobulin)**:
  - Dose: 2-3 g/kg over 2-3 days
  - Mechanism: Blocks Fas-mediated keratinocyte death
  - Evidence: Mixed results in studies
  - May benefit if given very early
- **Cyclosporine**:
  - Some data suggesting benefit
  - Dose: 3-5 mg/kg/day
  - Not widely used
- **Plasmapheresis, TNF inhibitors**: Case reports, not standard

**Multidisciplinary Team:**
- Dermatology, ophthalmology, pulmonology, infectious disease, nutrition, wound care, pain management

#### Prognosis
- **Mortality**: Depends on extent and SCORTEN score
- **Recovery**: Weeks for re-epithelialization
- **Long-term**: Ophthalmologic sequelae most common, cutaneous scarring
- **Recurrence**: If drug re-exposed (must be avoided)

#### Prevention
- **Genetic screening**: HLA-B*15:02 before carbamazepine (Asians), HLA-B*57:01 before abacavir
- **Allopurinol**: Start low dose, especially in renal impairment

### Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)

#### Overview
- **Also known as**: Drug-induced hypersensitivity syndrome (DIHS)
- **Mechanism**: Type IV delayed hypersensitivity + viral reactivation (HHV-6)
- **Latency**: 2-8 weeks (longer than typical drug eruption)
- **Prolonged course**: Weeks to months despite drug discontinuation
- **Mortality**: 10% (liver failure most common cause)

#### Pathophysiology
- **Genetic factors**: Slow acetylators, defects in drug detoxification
- **Viral reactivation**: HHV-6, HHV-7, EBV, CMV contribute to symptoms
- **Immune activation**: T-cell proliferation, eosinophilia, cytokine release

#### Clinical Presentation

**Triad:**
1. **Rash**
2. **Fever**
3. **Internal organ involvement**

**Cutaneous Manifestations:**
- **Onset**: 2-8 weeks after drug initiation
- **Morphology**: Initially morbilliform, becomes more severe
  - Erythematous macules and papules
  - Confluent erythema
  - May develop vesicles, pustules
  - Purpura possible
- **Distribution**: Generalized, starts on face/upper trunk
- **Facial edema**: Characteristic feature
- **Exfoliative dermatitis**: May progress

**Systemic Features:**
- **Fever**: High (>38.5°C), persistent
- **Lymphadenopathy**: Diffuse, tender
- **Hepatitis**: Most common visceral involvement (50-90%)
  - Elevated transaminases
  - May progress to fulminant hepatic failure
- **Hematologic**:
  - Eosinophilia (>1,000/μL or >10%)
  - Atypical lymphocytosis
  - Leukocytosis
- **Renal**: Interstitial nephritis (10-30%)
- **Pulmonary**: Pneumonitis (rare)
- **Cardiac**: Myocarditis (rare but potentially fatal)
- **Thyroiditis**: Can be delayed (weeks to months after resolution)

#### Common Causative Drugs
- **Anticonvulsants**: Aromatic anticonvulsants
  - Phenytoin (most common)
  - Carbamazepine
  - Phenobarbital
  - Lamotrigine (RegiSCAR: most common in study)
  - **Cross-reactivity**: 50-80% between aromatic anticonvulsants
- **Allopurinol**: Second most common cause
- **Sulfonamides**: Sulfasalazine, sulfamethoxazole
- **Antibiotics**: Minocycline, dapsone
- **Antiretrovirals**: Abacavir, nevirapine
- **Other**: Celecoxib, strontium ranelate

#### Diagnosis

**RegiSCAR Criteria:**
**Required (all 3):**
1. Hospitalization
2. Reaction suspected to be drug-related
3. Acute rash

**Additional criteria (score):**
- Fever ≥38.5°C (0-2 points)
- Lymphadenopathy ≥2 sites (1 point)
- Eosinophilia (1-2 points based on level)
- Atypical lymphocytes (1 point)
- Skin involvement >50% BSA (1 point)
- Biopsy suggesting DRESS (1 point)
- Organ involvement (1-2 points based on number of organs)

**Score interpretation:**
- <2: No DRESS
- 2-3: Possible
- 4-5: Probable
- >5: Definite

**Laboratory:**
- CBC with differential: Eosinophilia, atypical lymphocytes
- Liver function tests: Transaminitis, hyperbilirubinemia
- Renal function: Creatinine elevation
- Viral serologies: HHV-6 reactivation (research setting)
- Skin biopsy: Interface dermatitis, eosinophils

#### Management

**Immediate:**
- **Stop culprit drug**: Immediately (do not rechallenge)
- **Hospitalization**: Required for monitoring
- **Supportive care**: Fluids, nutrition

**Systemic Corticosteroids:**
- **Indications**: Most patients, especially with organ involvement
- **Dose**: Prednisone 0.5-1 mg/kg/day (or IV equivalent)
- **Duration**: Prolonged taper over weeks to months
  - Rapid taper may cause rebound
  - Typical: 6-12 weeks total
- **Monitoring**: Flare with taper requires dose increase

**Other Therapies (Refractory Cases):**
- **IVIG**: 2 g/kg over 2-5 days
- **Cyclosporine**: 3-5 mg/kg/day
- **Mycophenolate mofetil**: Steroid-sparing
- **Plasmapheresis**: Case reports

**Monitoring:**
- **Weekly labs initially**: CBC, LFTs, renal function
- **Follow-up**: Months after resolution
  - Liver function (autoimmune hepatitis can develop)
  - Thyroid function (delayed thyroiditis)
- **Vaccinations**: Check after immunosuppression

**Anticonvulsant Cross-Reactivity:**
- Avoid all aromatic anticonvulsants if DRESS from one
- Safer alternatives: Valproic acid, levetiracetam, gabapentin, pregabalin

#### Prognosis
- **Mortality**: 10%
- **Cause of death**: Hepatic failure (most common), myocarditis
- **Resolution**: Slow, weeks to months
- **Long-term sequelae**: Possible autoimmune conditions (thyroiditis, diabetes)

### Acute Generalized Exanthematous Pustulosis (AGEP)

#### Overview
- **Characterized by**: Acute, widespread, sterile pustules
- **Mechanism**: T-cell mediated, neutrophil recruitment
- **Latency**: Short (median 1 day for re-exposure, 11 days for first exposure)
- **Self-limited**: Usually resolves within 2 weeks

#### Clinical Presentation
- **Onset**: Acute, within 1-5 days of drug exposure (or 1 day if re-exposure)
- **Fever**: High (>38°C) in >90%
- **Rash**:
  - Widespread erythema
  - Hundreds of small (<5mm), non-follicular, sterile pustules on erythematous base
  - Distribution: Intertriginous areas (axillae, groin) and face first, then generalizes
- **Edema**: Facial and acral edema
- **Mucous membranes**: Limited involvement (<20%)
- **Desquamation**: Characteristic during resolution (after 1-2 weeks)

#### Laboratory
- **Leukocytosis**: Neutrophilic
- **Eosinophilia**: Mild, in some cases
- **Renal impairment**: Possible but usually mild
- **Hepatic**: Mild transaminitis possible

#### Common Causative Drugs
- **Antibiotics** (80%):
  - Beta-lactams: Ampicillin, amoxicillin
  - Macrolides: Azithromycin, clarithromycin
  - Quinolones
- **Calcium channel blockers**: Diltiazem, nifedipine
- **Antimalarials**: Hydroxychloroquine, chloroquine
- **Terbinafine**
- **Pristinamycin**

#### Diagnosis
- **Clinical**: Acute pustular eruption with fever
- **Skin biopsy**: Subcorneal or intraepidermal pustules, papillary dermal edema
- **Pustule culture**: Sterile (rule out infection)
- **EuroSCAR validation score**:
  - Morphology (pustules)
  - Course and resolution
  - Fever
  - Neutrophilia
  - Histology

#### Differential Diagnosis
- **Pustular psoriasis**: History of psoriasis, different distribution
- **Generalized pustular psoriasis of pregnancy**
- **Infection**: Bacterial, fungal (culture positive)
- **Toxic shock syndrome**: Different presentation

#### Management
- **Discontinue drug**: Usually resolves spontaneously after
- **Supportive care**:
  - Topical corticosteroids: Mid-potency
  - Emollients
  - Antihistamines if pruritic
- **Systemic corticosteroids**: Not usually necessary (self-limited)
- **Resolution**: 1-2 weeks
- **Prognosis**: Excellent (mortality <5%, usually in elderly with comorbidities)

### Drug-Induced Lupus Erythematosus (DILE)

#### Overview
- **Resembles**: Systemic lupus erythematosus (SLE)
- **Difference**: Resolves after drug discontinuation
- **Prevalence**: Uncommon
- **Latency**: Months to years of drug exposure

#### Clinical Presentation
- **Systemic symptoms**: Fever, malaise, arthralgias/arthritis (most common)
- **Cutaneous**: Less common than SLE
  - Photosensitive rash possible
  - Malar rash rare
- **Serositis**: Pleuritis, pericarditis (common in DILE)
- **Renal involvement**: Rare (unlike SLE)
- **CNS involvement**: Rare (unlike SLE)

#### Laboratory
- **ANA**: Positive (>95%)
- **Anti-histone antibodies**: Positive (95%) - suggestive of DILE
- **Anti-dsDNA**: Negative (if positive, suggests SLE)
- **Anti-Sm**: Negative (if positive, suggests SLE)
- **Complement**: Normal (unlike SLE where often low)

#### Common Causative Drugs
**High risk:**
- **Hydralazine**: 5-20% develop DILE
- **Procainamide**: 20-30% with prolonged use
- **Isoniazid**
- **Quinidine**

**Moderate risk:**
- **Minocycline**: Subacute cutaneous lupus-like
- **Anti-TNF agents**: Etanercept, infliximab, adalimumab
- **Interferon-alpha**
- **Terbinafine**

**Low risk:**
- **Carbamazepine**
- **Phenytoin**
- **Lithium**
- **Chlorpromazine**

#### Diagnosis
- **Clinical**: Lupus-like symptoms in patient on known causative drug
- **Laboratory**: Positive ANA, anti-histone antibodies
- **Exclusion**: Idiopathic SLE (anti-dsDNA, anti-Sm negative; normal complement)

#### Management
- **Discontinue drug**: Essential
- **NSAIDs**: For arthralgias, serositis
- **Corticosteroids**: For severe symptoms (serositis, arthritis)
  - Prednisone 0.5-1 mg/kg/day, taper over weeks
- **Resolution**: Symptoms improve within weeks, serologies normalize over months
- **Prognosis**: Excellent, complete resolution expected

## Drug Testing and Desensitization

### Drug Allergy Testing

#### Skin Testing
- **Indications**: Confirm IgE-mediated allergy (especially penicillin)
- **Types**:
  - Skin prick test: First step
  - Intradermal test: If prick negative and still suspicion
- **Penicillin testing**:
  - Pre-Pen (benzylpenicilloyl polylysine), penicillin G
  - Negative predictive value >95%
- **Limitations**: Only for IgE-mediated (not for T-cell mediated)
- **Contraindications**: Recent severe reaction (SJS/TEN, DRESS)

#### Patch Testing
- **Indications**: Type IV reactions (T-cell mediated)
- **Technique**: Apply drug to back, occlude 48 hours, read at 48 and 72-96 hours
- **Limited availability**: Not standardized for most drugs

#### In Vitro Testing
- **Drug-specific IgE**: Available for few drugs (penicillin, rare others)
- **Basophil activation test**: Research setting
- **Lymphocyte transformation test**: For DRESS, limited availability

### Drug Challenge
- **Oral provocation test**: Gradual dose escalation under observation
- **Indications**: Low-risk history, negative skin testing, or if testing unavailable
- **Setting**: Hospital with resuscitation equipment
- **Contraindications**: History of SJS/TEN, DRESS, anaphylaxis

### Desensitization

#### Indications
- **Essential drug with no alternative**
- **Confirmed IgE-mediated allergy**
- **Common scenarios**: Penicillin for syphilis in pregnant women, chemotherapy agents

#### Mechanism
- **Temporary tolerance**: Gradual dose escalation
- **Mast cell**: Becomes less responsive
- **Not permanent**: Tolerance lost after drug stopped

#### Procedure
- **Setting**: ICU or monitored setting with resuscitation equipment
- **Premedication**: Antihistamines, consider corticosteroids
- **Protocol**: Incremental doses starting at 1/1000 to 1/10,000 of full dose
  - Double dose every 15-30 minutes
  - Goal: Achieve full therapeutic dose in 4-12 hours
- **Maintenance**: Continue drug without interruption (tolerance lost if stopped)

#### Protocols
- **Penicillin**: Standard rapid desensitization protocols available
- **Chemotherapy**: Agent-specific protocols (platinum agents, taxanes)
- **Aspirin**: For cardiac disease, gradual escalation
- **Other**: Trimethoprim-sulfamethoxazole, allopurinol

#### Contraindications
- **Non-IgE-mediated reactions**: SJS/TEN, DRESS, organ-specific toxicity
- **Severe reactions**: Previous anaphylaxis with hemodynamic instability

## Key Points

- Exanthematous (morbilliform) drug eruption is the most common pattern (90%), typically occurring 7-14 days after drug initiation and self-limited
- Antibiotics (especially beta-lactams and sulfonamides), anticonvulsants, and NSAIDs are the most common causative drugs across reaction types
- Severe cutaneous adverse reactions (SJS/TEN, DRESS, AGEP) are rare but life-threatening, requiring immediate drug discontinuation and hospitalization
- SJS/TEN characterized by fever, mucosal involvement, skin detachment, and positive Nikolsky sign; mortality 25-35% for TEN
- DRESS presents with fever, rash, facial edema, eosinophilia, and internal organ involvement (especially hepatitis) 2-8 weeks after drug initiation
- Management of severe drug reactions centers on immediate drug discontinuation, supportive care, and multidisciplinary involvement
- Fixed drug eruption recurs at same anatomic site with drug re-exposure and leaves residual hyperpigmentation (hallmark feature)
- Genetic screening (HLA-B*15:02 before carbamazepine in Asians, HLA-B*57:01 before abacavir) can prevent severe reactions
- Drug desensitization can be performed for IgE-mediated reactions when no alternative exists, but is contraindicated for SJS/TEN and DRESS
- Patient education and documentation of drug allergies are essential to prevent re-exposure and guide future treatment

## References

1. Shiohara T, Mizukawa Y. Drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS): An update in 2019. Allergol Int. 2019;68(3):301-308.
2. Lerch M, Mainetti C, Terziroli Beretta-Piccoli B, Harr T. Current perspectives on Stevens-Johnson syndrome and toxic epidermal necrolysis. Clin Rev Allergy Immunol. 2018;54(1):147-176.
3. Wolfson AR, Zhou L, Li Y, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome identified in the electronic health record allergy module. J Allergy Clin Immunol Pract. 2019;7(2):633-640.
